Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I

European Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2011, Pages 2264-2273

  Qiao, Yuqin ^a   Gao, Jinbo ^a   Qiu, Yongge ^a   Wu, Long ^a   Guo, Fei ^a   Kam Wing Lo, Kenneth ^a   Li, Ding ^b  

^a CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cancer; Dual protein inhibitor; Farnesyltransferase; Geranylgeranyltransferase; Piperazinedione

Indexed keywords

GERANYLGERANYLTRANSFERASE I INHIBITOR; ISOPRENOID; N (2 FURANMETHYL) 6 (1 (2 METHYLTHIO) ETHYL) PIPERAZINE 2,5 DIONE; N (2 FURANMETHYL) 6 (1H INDOL 3 YL)PIPERAZINE 2,5 DIONE; N (2 FURANMETHYL) 6 (3 (3H IMIDAZOL 4 YL))PIPERAZINE 2,5 DIONE; N (2 FURANMETHYL) 6 (4 METHOXYBENZYL)PIPERAZINE 2,5 DIONE; N (2 FURANMETHYL) 6 (BENZYL METHYL)PIPERAZINE 2,5 DIONE; N (2 FURANMETHYL) 6 BENZYLPIPERAZINE 2,5 DIONE; N (2 FURANMETHYL) 6 ISO PROPYLPIPERAZINE 2,5 DIONE; N (2 FURANMETHYL) 6 METHYLPIPERAZINE 2,5 DIONE; N (3,5 DICHLORO 2 METHOXYBENZYL) 6 (1H INDOL 3 YL)PIPERAZINE 2,5 DIONE; N (4 (3 CHLOROPHENOXY)BENZYL) 6 (1H INDOL 3 YL)PIPERAZINE 2,5 DIONE; N (4 (3,4 DICHLOROPHENOXY)BENZYL) 6 (1H INDOL 3 YL)PIPERAZINE 2,5 DIONE; N (4 (4 MORPHOLINYL)BENZYL) 6 (1H INDOL 3 YL)PIPERAZINE 2,5 DIONE; N (4 BROMOBENZYL) 6 (1H INDOL 3 YL)PIPERAZINE 2,5 DIONE; N (4 CHLOROBENZYL) 6 (1H INDOL 3 YL)PIPERAZINE 2,5 DIONE; N (4 CYANOBENZYL) 6 (1H INDOL 3 YL)PIPERAZINE 2,5 DIONE; N (4 FLUOROBENZYL) 6 (1H INDOL 3 YL)PIPERAZINE 2,5 DIONE; N 4 (2 FURANMETHYL) 6 ISO BUTYLPIPERAZINE 2,5 DIONE; N 4 METHOXYBENZYL 6 (1 (2 METHYLTHIO)ETHYL) PIPERAZINE 2,5 DIONE; N 4 METHOXYBENZYL 6 (1H INDOL 3 YL)PIPERAZINE 2,5 DIONE; N 4 METHOXYBENZYL 6 (3 (3H IMIDAZOL 4 YL)) PIPERAZINE 2,5 DIONE; N 4 METHOXYBENZYL 6 (4 METHOXYBENZYL)PIPERAZINE 2,5 DIONE; N 4 METHOXYBENZYL 6 (BENZYL METHYL)PIPERAZINE 2,5 DIONE; N 4 METHOXYBENZYL 6 BENZYLPIPERAZINE 2,5 DIONE; N 4 METHOXYBENZYL 6 ISO BUTYLPIPERAZINE 2,5 DIONE; N 4 METHOXYBENZYL 6 ISO PROPYLPIPERAZINE 2,5 DIONE; N 4 METHOXYBENZYL 6 METHYLPIPERAZINE 2,5 DIONE; PIPERAZINEDIONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IN VIVO STUDY; MOLECULAR DOCKING; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ALKYL AND ARYL TRANSFERASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PIPERAZINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955628599     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.03.007     Document Type: Article

References (46)

1. P.A. Konstantinopoulos, M.V. Karamouzis, A.G. Papavassiliou, Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets, Nat. Rev. Drug. Discov. 6 (2007) 541-555. (Pubitemid 47019443)
2. J.L. Hougland, C.A. Fierke, Getting a handle on protein prenylation, Nat. Chem. Biol. 5 (2009) 197-198.
3. S.M. Sebti, C.J. Der, Opinion e searching for the elusive targets of farnesyltransferase inhibitors, Nat. Rev. Cancer. 3 (2003) 945-951. (Pubitemid 37500179)
4. M.H. Gelb, L. Brunsveld, C.A. Hrycyna, S. Michaelis, F. Tamanoi, W.C. Van Voorhis, H. Waldmann, Therapeutic intervention based on protein prenylation and associated modifications, Nat. Chem. Biol. 2 (2006) 518-528. (Pubitemid 44413234)
5. A. Rak, O. Pylypenko, A. Niculae, K. Pyatkov, R.S. Goody, K. Alexandrov, Structure of the Rab7: REP-1 complex: insights into the mechanism of rab prenylation and choroideremia disease, Cell 117 (2004) 749-760. (Pubitemid 38748891)
6. S.B. Long, P.J. Casey, L.S. Beese, Reaction path of protein farnesyltransferase at atomic resolution, Nature 419 (2002) 645-650.
7. J. Marji, S.I. O'Donoghue, D. McClintock, V.P. Satagopam, R. Schneider, D. Ratner, H.J. Worman, L.B. Gordon, K. Djabali, Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition, Plos One 5 (2010).
8. A.M. Winter-Vann, P.J. Casey, Opinion - post-prenylation-processing enzymes as new targets in oncogenesis, Nat. Rev. Cancer. 5 (2005) 405-412. (Pubitemid 40637832)
9. A.G. Agrawal, R.R. Somani, Farnesyltransferase inhibitor as anticancer agent, Mini Rev. Med. Chem. 9 (2009) 638-652.
10. S. Fletcher, C.G. Cummings, K. Rivas, W.P. Katt, C. Horney, F.S. Buckner, D. Chakrabarti, S.M. Sebti, M.H. Gelb, W.C. Van Voorhis, A.D. Hamilton, Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation, J. Med. Chem. 51 (2008) 5176-5197.
11. L.G. Fong, D. Frost, M. Meta, X. Qiao, S.H. Yang, C. Coffinier, S.G. Young, A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria, Science 311 (2006) 1621-1623.
12. J.L. Harousseau, Farnesyltransferase inhibitors in hematologic malignancies, Blood. Rev. 21 (2007) 173-182.
13. J.L. Harousseau, J.E. Lancet, J. Reiffers, B. Lowenberg, X. Thomas, F. Huguet, P. Fenaux, S. Zhang, W. Rackoff, P. De Porre, R. Stone, F. Amlsg, A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia, Blood 109 (2007) 5151-5156. (Pubitemid 46890529)
14. B.C. Capell, M. Olive, M.R. Erdos, K. Cao, D.A. Faddah, U.L. Tavarez, K.N. Conneely, X. Qu, H. San, S.K. Ganesh, X. Chen, H. Avallone, F.D. Kolodgie, R. Virmani, E.G. Nabel, F.S. Collins, A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model, Proc. Natl. Acad. Sci. U S A 105 (2008) 15902-15907.
15. M.A. Hast, S. Fletcher, C.G. Cummings, E.E. Pusateri, M.A. Blaskovich, K. Rivas, M.H. Gelb, W.C. Van Voorhis, S.M. Sebti, A.D. Hamilton, L.S. Beese, Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase, Chem. Biol. 16 (2009) 181-192.
16. R.E. Marks, A.W. Ho, C. Robbel, T. Kuna, S. Berk, T.F. Gajewski, Farnesyltransferase inhibitors inhibit T-cell cytokine production at the post-transcriptional level, Blood 110 (2007) 1982-1988. (Pubitemid 47443912)
17. M.C. Seabra, Y. Reiss, P.J. Casey, M.S. Brown, J.L. Goldstein, Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit, Cell 65 (1991) 429-434. (Pubitemid 121002052)
18. S.F. Sousa, P.A. Fernandes, M.J. Ramos, The search for the mechanism of the reaction catalyzed by farnesyltransferase, Chem A Eur J 15 (2009) 4243-4247.
19. H.W. Park, S.R. Boduluri, J.F. Moomaw, P.J. Casey, L.S. Beese, Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution, Science 275 (1997) 1800-1804. (Pubitemid 27136719)
20. S.B. Long, P.J. Hancock, A.M. Kral, H.W. Hellinga, L.S. Beese, The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics, Proc. Natl. Acad. Sci. U S A 98 (2001) 12948-12953. (Pubitemid 33051300)
21. D.A. Tobin, J.S. Pickett, H.L. Hartman, C.A. Fierke, J.E. Penner-Hahn, Structural characterization of the zinc site in protein farnesyltransferase, J. Am. Chem. Soc. 125 (2003) 9962-9969. (Pubitemid 36994926)
22. K.L. Terry, P.J. Casey, L.S. Beese, Conversion of protein farnesyltransferase to a geranylgeranyltransferase, Biochemistry 45 (2006) 9746-9755. (Pubitemid 44257422)
23. K.T. Lane, L.S. Beese, Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I, J. Lipid. Res. 47 (2006) 681-699.
24. J.L. Hougland, K.A. Hicks, H.L. Hartman, R.A. Kelly, T.J. Watt, C.A. Fierke, Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities, J. Mol. Biol. 395 (2010) 176-190.
25. N.E. Kohl, S.D. Mosser, S.J. deSolms, E.A. Giuliani, D.L. Pompliano, S.L. Graham, R.L. Smith, E.M. Scolnick, A. Oliff, J.B. Gibbs, Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor, Science 260 (1993) 1934-1937.
26. N.E. Kohl, C.A. Omer, M.W. Conner, N.J. Anthony, J.P. Davide, S.J. deSolms, E.A. Giuliani, R.P. Gomez, S.L. Graham, K. Hamilton, et al., Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice, Nat. Med. 1 (1995) 792-797.
27. I.M. Bell, Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy? J. Med. Chem. 47 (2004) 1869-1878.
28. R.J. Doll, P. Kirschmeier, W.R. Bishop, Farnesyltransferase inhibitors as anticancer agents: critical crossroads, Curr. Opin. Drug. Discov. Devel. 7 (2004) 478-486. (Pubitemid 44383554)
29. S.F. Sousa, P.A. Fernandes, M.J. Ramos, Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem, Curr. Med. Chem. 15 (2008) 1478-1492. (Pubitemid 351997780)
30. S.J. DeSolms, T.M. Ciccarone, S.C. MacTough, A.W. Shaw, C.A. Buser, M. Ellis-Hutchings, C. Fernandes, K.A. Hamilton, H.E. Huber, N.E. Kohl, R.B. Lobell, R.G. Robinson, N.N. Tsou, E.S. Walsh, S.L. Graham, L.S. Beese, J.S. Taylor, Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents, J. Med. Chem. 46 (2003) 2973-2984.
31. N.E. Martin, T.B. Brunner, K.D. Kiel, T.F. DeLaney, W.F. Regine, M. Mohiuddin, E.F. Rosato, D.G. Haller, J.P. Stevenson, D. Smith, B. Pramanik, J. Tepper, W.K. Tanaka, B. Morrison, P. Deutsch, A.K. Gupta, R.J. Muschel, W.G. McKenna, E.J. Bernhard, S.M. Hahn, A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778123 and radiotherapy for locally advanced pancreatic cancer, Clin. Cancer. Res. 10 (2004) 5447-5454. (Pubitemid 39100482)
32. T.S. Reid, S.B. Long, L.S. Beese, Crystallographic analysis reveals that anticancer clinical candidate L-778123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes, Biochemistry 43 (2004) 9000-9008. (Pubitemid 38924434)
33. M.R. Graaf, D.J. Richel, C.J.F. van Noorden, H.J. Guchelaar, Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer, Cancer. Treat. Rev. 30 (2004) 609-641. (Pubitemid 39451828)
34. K. van der Weide, S.D.P.W.M. de Jonge-Peeters, F. Kuipers, E.G.E. Devries, E. Vellenga, Combining Simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34 (+) acute myeloid leukemia samples, Clin. Cancer. Res. 15 (2009) 3076-3083.
35. N.E. Ready, A. Lipton, Y.L. Zhu, P. Statkevich, E. Frank, D. Curtis, R.M. Bukowski, Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors, Clin. Cancer. Res. 13 (2007) 576-583. (Pubitemid 46225364)
36. D.S. Hong, S.M. Sebti, R.A. Newman, M.A. Blaskovich, L. Ye, R.F. Gagel, S. Moulder, J.J. Wheler, A. Naing, N.M. Tannir, C.S. Ng, S.I. Sherman, A.K. El Naggar, R. Khan, J. Trent, J.J. Wright, R. Kurzrock, Phase I trial of a combination of the multikinase inhibitor Sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies, Clin. Cancer. Res. 15 (2009) 7061-7068.
37. T. Li, P.J. Christos, J.A. Sparano, D.L. Hershman, S. Hoschander, K. O'Brien, J.J. Wright, L.T. Vahdat, Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205, Ann. Oncol. 20 (2009) 642-647.
38. D.J. McNamara, E. Dobrusin, D.M. Leonard, K.R. Shuler, J.S. Kaltenbronn, J. Quin, S. Bur, C.E. Thomas, A.M. Doherty, J.D. Scholten, K.K. Zimmerman, B.S. Gibbs, R.C. Gowan, M.P. Latash, W.R. Leopold, S.A. Przybranowski, J.S. SeboltLeopold, C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of ras farnesyltransferase, cellular activity, and anticancer activity in mice, J. Med. Chem. 40 (1997) 3319-3322.
39. J.L. Hougland, C.L. Lamphear, S.A. Scott, R.A. Gibbs, C.A. Fierke, Context-dependent substrate recognition by protein farnesyltransferase, Biochemistry 48 (2009) 1691-1701.
40. K. Koerberple, G. Massiot, Total synthesis of nosiheptide - synthesis of thiazole fragments, J. Heterocyclic Chem. 32 (1995) 1309-1315.
41. Y.Q. Fu, B. Xu, X.M. Zou, C. Ma, X.M. Yang, K. Mou, G. Fu, Y. Lu, P. Xu, Design and synthesis of a novel class of furan-based molecules as potential 20S proteasome inhibitors, Bioorg. Med. Chem. Lett. 17 (2007) 1102-1106. (Pubitemid 46178542)
42. S.D. Bull, S.G. Davies, A.C. Garner, A.L. Parkes, P.M. Roberts, T.G.R. Sellers, A.D. Smith, J.A. Tamayo, J.E. Thomson, R.J. Vickers, On the origins of diastereoselectivity in the alkylation of diketopiperazine enolates, New J. Chem. 31 (2007) 486-495.
43. R. Thomsen, M.H. Christensen, MolDock: a new technique for high-accuracy molecular docking, J. Med. Chem. 49 (2006) 3315-3321.
44. S.L. Graham, S.J. Desolms, E.A. Giuliani, N.E. Kohl, S.D. Mosser, A.I. Oliff, D.L. Pompliano, E. Rands, M.J. Breslin, A.A. Deana, V.M. Garsky, T.H. Scholz, J.B. Gibbs, R.L. Smith, Pseudopeptide inhibitors of Ras farnesyl-protein transferase, J. Med. Chem. 37 (1994) 725-732.
45. P.B. Cassidy, J.M. Dolence, C.D. Poulter, Continuous fluorescence assay for protein prenyltransferases, Meth. Enzymol. 250 (1995) 30-43.
46. W.C. Pickett, F.L. Zhang, C. Silverstrim, S.R. Schow, M.M. Wick, S.S. Kerwar, A fluorescence assay for geranylgeranyl transferase type I, Anal. Biochem. 225 (1995) 60-63.